EMEA-000527-PIP05-17
Key facts
| Invented name |
Lucentis
|
| Active substance |
ranibizumab
|
| Therapeutic area |
Ophthalmology
|
| Decision number |
P/0142/2018
|
| PIP number |
EMEA-000527-PIP05-17
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Diabetic retinopathy
|
| Route(s) of administration |
Intravitreal use
|
| Contact for public enquiries |
Novartis Europharm Limited
E-mail: paediatric.enquiries@novartis.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|